Peri‐operative and local control outcomes of robot‐assisted partial nephrectomy vs percutaneous cryoablation for renal masses: comparison after matching on radiological stage and renal score

Fraisse, G; Colleter, L.; Peyronnet, B.; Khene, Z.; Mandoorah, Qusay; Soorojebally, Yanish; Bourgi, Ali; Taille, Alexandre de la; Rouprêt, Morgan; Kerviler, É. de; Desgrandchamps, François; Bensalah, Karim; Masson-Lecomte, A.

doi:10.1111/bju.14530

Cited by 16 publications

(30 citation statements)

References 27 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mean follow-up period of every group in all studies was up to 6 months. 8 eligible studies got a score ≥ 7 according to Newcastle-Ottawa Scale (Table S1) 8, 14, 16-18, 20, 24, 25, while the remaining ones were marked as moderate quality studies 2, 3, 10, 13, 19, 21-23, 26. Most studies did not describe clearly about how to deal with missing data or intention-to-treat analyses.…”

Section: Resultsmentioning

confidence: 99%

Cryoablation versus Partial Nephrectomy for Clinical Stage T1 Renal Masses: A Systematic Review and Meta-Analysis

et al. 2019

View full text Add to dashboard Cite

Introduction : Cryoablation has been considered as the most efficacious ablative alternative to partial nephrectomy (PN) for selected patients. Our objective is to assess the existing evidence relating to the safety and efficacy of cryoablation compared with PN for clinical T1 renal masses. Materials and Methods : A comprehensive search of PMC, EMBASE, and the Cochrane Library was conducted to identify studies containing comparison of cryoablation and PN. By utilizing those included studies, a systematic review and cumulative meta-analyses were performed to assess the safety and efficacy between cryoablation and PN for T1 renal masses. Results : 17 retrospective studies providing available data were included in our study. Significant differences were found about all oncological variables including all-cause death, cancer-specific death, metastasis and local-recurrence (p < 0.001, p = 0.03, p < 0.001, and p < 0.001, respectively) between the PN group and the cryoablation group. The mean difference between two groups for percent estimated glomerular filtration rate decrease and creatinine increase was -4.84 and 0.15 respectively (p < 0.001 and p = 0.006, respectively). The incidences of overall and postoperative complications in the PN group were significantly higher than that in the cryoablation group (p = 0.001 and p < 0.001, respectively), but the result about intraoperative complications didn't show a significant difference between the two groups (p = 0.53). Conclusions : Comparing with PN, cryoablation for clinical T1 renal tumors is associated with poorer oncological outcomes, but the existing disadvantages are accompanied by lower rate of overall and postoperative complications and superior renal functional preservation. For patients with imperative indications for nephron-sparing surgery who can't risk more invasive PN, cryoablation could be an attractive option. Owing to the inherent limitations of eligible studies, conclusions drawn from our meta-analyses should be interpreted cautiously and be confirmed further with well-designed randomized controlled trials with extensive follow-up length.

show abstract

Section: Resultsmentioning

confidence: 99%

Cryoablation versus Partial Nephrectomy for Clinical Stage T1 Renal Masses: A Systematic Review and Meta-Analysis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Regarding the oncological outcomes, our series showed 0.8% of recurrences and 0.7% of metastases within a median follow-up of 37 mo, which is limited. Fraisse et al [31] reported an absolute recurrence rate of 8.4% in patients, who underwent percutaneous cryoablation, with a mean clinical tumor size of 25.9 cm and a mean follow of 5 yr.…”

Section: Discussionmentioning

confidence: 99%

Robotic-assisted Partial Nephrectomy for “Very Small” (<2 cm) Renal Mass: Results of a Multicenter Contemporary Cohort

Carbonara

Simone

Minervini

et al. 2021

European Urology Focus

View full text Add to dashboard Cite

“…In addition, RAPN is more useful than open partial nephrectomy and laparoscopic partial nephrectomy 3 . And the local recurrence rate of T1 renal tumors after renal cryoablation was significantly higher than that after RAPN 4 . Although there have been reports of RAPN in horseshoe kidney for benign tumor and heminephrectomy using a robotic device, 2 there have been no reports of RAPN for renal cell carcinoma in a horseshoe kidney, in particular, that treated via a retroperitoneal approach (Table 1).…”

Section: Discussionmentioning

confidence: 99%

Renal cell carcinoma in a horseshoe kidney treated with robot-assisted partial nephrectomy

Yamamichi

Nakata

Tsujimura

et al. 2019

Urology Case Reports

View full text Add to dashboard Cite

Horseshoe kidney is one of the most common congenital renal fusion anomalies and the incidence of renal cell carcinoma in horseshoe kidney is predicted to be approximately 5.2/100000 individuals. Because horseshoe kidney merges malformations and vascular changes, open surgery is the standard for treatment. There are no reports of robot-assisted partial nephrectomy (RAPN) for renal cell carcinoma in horseshoe kidney. We describe for the first time the safety and the utility of RAPN in a horseshoe kidney with renal cell carcinoma.

show abstract

Peri‐operative and local control outcomes of robot‐assisted partial nephrectomy vs percutaneous cryoablation for renal masses: comparison after matching on radiological stage and renal score

Cited by 16 publications

References 27 publications

Cryoablation versus Partial Nephrectomy for Clinical Stage T1 Renal Masses: A Systematic Review and Meta-Analysis

Cryoablation versus Partial Nephrectomy for Clinical Stage T1 Renal Masses: A Systematic Review and Meta-Analysis

Robotic-assisted Partial Nephrectomy for “Very Small” (<2 cm) Renal Mass: Results of a Multicenter Contemporary Cohort

Renal cell carcinoma in a horseshoe kidney treated with robot-assisted partial nephrectomy

Contact Info

Product

Resources

About